|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Pitavastatin#Drug Interactions]] |
| {{Pitavastatin}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Drug Interactions==
| |
| | |
| ===Cyclosporine===
| |
| | |
| [[Cyclosporine]] significantly increased pitavastatin exposure. Co-administration of [[cyclosporine]] with LIVALO is contraindicated [see Contraindications (4) and Clinical Pharmacology (12.3)].
| |
| | |
| ===Erythromycin===
| |
| | |
| [[Erythromycin]] significantly increased pitavastatin exposure. In patients taking [[erythromycin,]] a dose of LIVALO 1 mg once daily should not be exceeded [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].
| |
| | |
| ===Rifampin===
| |
| | |
| [[Rifampin]] significantly increased pitavastatin exposure. In patients taking [[rifampin,]] a dose of LIVALO 2 mg once daily should not be exceeded [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)].
| |
| | |
| 7.4 Gemfibrozil
| |
| | |
| Due to an increased risk of [[myopathy]]/[[rhabdomyolysis]] when [[HMG-CoA]] reductase inhibitors are coadministered with [[gemfibrozil]], concomitant administration of LIVALO with [[gemfibrozil]] should be avoided.
| |
| | |
| ===Other Fibrates===
| |
| | |
| Because it is known that the risk of [[myopathy]] during treatment with [[HMG-CoA]] reductase inhibitors is increased with concurrent administration of other [[fibrate]]s, LIVALO should be administered with caution when used concomitantly with other [[fibrate]]s [see Warnings and Precautions (5.1), and Clinical Pharmacology (12.3)].
| |
| | |
| ===Niacin===
| |
| | |
| The risk of skeletal muscle effects may be enhanced when LIVALO is used in combination with [[niacin]]; a reduction in LIVALO dosage should be considered in this setting[see Warnings and Precautions (5.1)].
| |
| | |
| ===Colchicine===
| |
| | |
| Cases of [[myopathy]], including [[rhabdomyolysis]], have been reported with [[HMG-CoA]] reductase inhibitors coadministered with [[colchicine]], and caution should be exercised when prescribing LIVALO with [[colchicine]].
| |
| | |
| ===Warfarin===
| |
| | |
| LIVALO had no significant pharmacokinetic interaction with R- and S- [[warfarin]]. LIVALO had no significant effect on prothrombin time (PT) and international normalized ratio (INR) when administered to patients receiving chronic [[warfarin]] treatment [see Clinical Pharmacology (12.3)]. However, patients receiving [[warfarin]] should have their PT and INR monitored when pitavastatin is added to their therapy.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = LIVALO (PITAVASTATIN CALCIUM) TABLET, FILM COATED [KOWA PHARMACEUTICALS AMERICA, INC. ] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=44dcbf97-99ec-427c-ba50-207e0069d6d2 | publisher = | date = | accessdate = 14 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| {{statins}}
| |
| | |
| [[Category:Statins]]
| |
| [[Category:Quinolines]]
| |
| [[Category:Diols]]
| |
| [[Category:Carboxylic acids]]
| |
| [[Category:Organofluorides]]
| |
| [[Category:Cyclopropanes]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |